Heightened intrathecal release of soluble CD137 in patients with multiple sclerosis

European Journal of Neurology

Volumn 9, Issue 1, 2002, Pages 49-54

  Sharief, M K ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; CD137; Cerebrospinal fluid; Intrathecal compartment; Multiple sclerosis

Indexed keywords

BRAIN PROTEIN; CD137 ANTIGEN; FAS ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BRAIN LEVEL; BRAIN REGION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; FEMALE; HUMAN; IMMUNOGLOBULIN PRODUCTION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION;

ADULT; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD95; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MULTIPLE SCLEROSIS; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; SPINAL CORD; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036388529     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2002.00323.x     Document Type: Article

References (32)

1. Alderson MR (1994). Regulation of immune responses by the ligands for CD27, CD30, and 4-1BB. Circ Shock 44:73-76.
2. Alderson MR, Smith CA, Tough TW et al. (1994). Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 24:2219-2227.
3. Antel J (1999). Multiple sclerosis-emerging concepts of disease pathogenesis. J Neuroimmunol 98:45-48.
4. Bansil S, Holtz CR, Cook SD, Rohowsky-Kochan C (1997). Serum sAPO-1/Fas levels in multiple sclerosis. Acta Neurol Scand 95:208-210.
5. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G (1996). Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signalling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 156:13-17.
6. Cheng J, Zhou T, Liu C, Shapiro JP et al. (1994). Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762.
7. Ciusani E, Frigerio S, Gelati M et al. (1998). Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 82:5-12.
8. Correale J, Gilmore W, Li S et al. (2000). Resistance to glucocorticoid-induced apoptosis in PLP peptide-specific T cell clones from patients with progressive MS. J Neuroimmunol 109:197-210.
9. Curto M, Sogos V, Reali C, Gremo F (1999). Expression of CD137, a member of the tumour necrosis factor receptor superfamily, in the developing human brain [abstract]. J Neurochem 73:168.
10. Garni-Wagner BA, Lee ZH, Kim YJ et al. (1996). 4-1BB is expressed on CD45RAhiROhi transitional T cell in humans. Cell Immunol 169:91-98.
11. Inoue A, Koh CS, Sakai T et al. (1997). Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J Neuroimmunol 75:141-146.
12. Kienzle G, von Kempis J (2000). CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. Int Immunol 12:73-82.
13. Kishimoto T, Goyert S, Kikutani H et al. (1997). Update of CD antigens. J Immunol 158:3035-3036.
14. Kwon BS, Weissman SM (1989). cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 86:1963-1967.
15. Melero I, Shuford WW, Newby SA et al. (1997). Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682-685.
16. Michel J, Langstein J, Hofstadter F, Schwarz H (1998). A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur J Immunol 28:290-295.
17. Michel J, Pauly S, Langstein J, Krammer PH, Schwarz H (1999). CD137-induced apoptosis is independent of CD95. Immunology 98:42-46.
18. Mountz JD, Zhou T, Wu J, Wang W, Su X, Cheng J (1995). Regulation of apoptosis in immune cells. J Clin Immunol 15:1-16.
19. Pender MP (1998). Genetically determined failure of activation-induced apoptosis of autoreactive T-cells as a cause of multiple sclerosis. Lancet 351:978-981.
20. Pollok KE, Kim YJ, Zhou Z et al. (1993). Inducible T-cell antigen 4-1BB. Analysis of expression and function. J Immunol 150:771-781.
21. Reiber H (1998). Cerebrospinal fluid - physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler 4:99-107.
22. Schwarz H, Tuckwell J, Lotz M (1993). A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family. Gene 134:295-298.
23. Schwarz H, Valbracht J, Tuckwell J, von Kempis J, Lotz M (1995). ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 85:1043-1052.
24. Schwarz H, Blanco FJ, von Kempis J, Valbracht J, Lotz M (1996). ILA, a member of the human nerve growth factor/tumor necrosis factor receptor family, regulates T-lymphocyte proliferation and survival. Blood 87:2839-2845.
25. Sharief MK, Thompson EJ (1989). Immunoglobulin M in the cerebrospinal fluid: an indicator of recent immunological stimulation. J Neurol Neurosurg Psychiatry 52:949-953.
26. Sharief MK, Hentges R (1991). Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 325:467-472.
27. Sharief MK, Thompson EJ (1991). Intrathecal immunoglobulin M synthesis in multiple sclerosis. Relationship with clinical and cerebrospinal fluid parameters. Brain 114:181-195.
28. Sharief MK, Keir G, Thompson EJ (1990). Intrathecal synthesis of IgM in neurological diseases: a comparison between detection of oligoclonal bands and quantitative estimation. J Neurol Sci 96:131-142.
29. Sharief MK, Hentges R, Thompson EJ (1992). Determination of interleukin-2 in cerebrospinal fluid by a sensitive enzyme-linked immunosorbent assay. J Immunol Meth 147:51-56.
30. Weller M, Malipiero U, Rensing-Ehl A, Barr PJ, Fontana A (1995). Fas/Apo-1 gene transfer for human malignant glioma. Cancer Res. 55:2936-2944.
31. Zipp F, Otzelberger K, Dichgans J, Martin R, Weller M (1998). Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis. J Neuroimmunol 86:151-154.
32. Zumkeller W, Schofield PN (1995). Growth factors, cytokines and soluble forms Hœ receptor molecules in c'fcer patients. Anticancer Res 28:343-348.